Barrow, Hanley, Mewhinney & Strauss’s Core Laboratories CLB Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-323	Closed	-$5.42K	–	383
2026 Q1	$5.42K	Hold	323	–	–	﹤0.01%	263
2025 Q4	$5.18K	Hold	323	–	–	﹤0.01%	269
2025 Q3	$3.99K	Hold	323	–	–	﹤0.01%	289
2025 Q2	$3.72K	Hold	323	–	–	﹤0.01%	271
2025 Q1	$4.84K	Hold	323	–	–	﹤0.01%	256
2024 Q4	$5.59K	Hold	323	–	–	﹤0.01%	265
2024 Q3	$5.99K	Hold	323	–	–	﹤0.01%	260
2024 Q2	$6.55K	Buy	323 +147	+84%	+$2.6K	﹤0.01%	228
2024 Q1	$3.01K	Hold	176	–	–	﹤0.01%	254
2023 Q4	$3.11K	Buy	176 +90	+105%	+$1.81K	﹤0.01%	254
2023 Q3	$2.06K	Buy	+86	New	+$2.11K	﹤0.01%	272

Other funds holding CLB

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Barrow, Hanley, Mewhinney & Strauss's CLB Position: Q2 2026 in Review

Barrow, Hanley, Mewhinney & Strauss sold out of Core Laboratories (CLB) in Q2 2026, closing a stake of 323 shares — an estimated $5.42K sold.

Barrow, Hanley, Mewhinney & Strauss first reported a position in CLB in Q3 2023 and held it in 11 quarters. The position peaked at $6.55K in Q2 2024. 186 funds tracked by Wall St. Rank hold CLB as of Q2 2026.

Barrow, Hanley, Mewhinney & Strauss reported no remaining Core Laboratories position as of Q2 2026 after selling out during the quarter.
Barrow, Hanley, Mewhinney & Strauss sold 323 Core Laboratories shares in Q2 2026, an estimated $5.42K.
Barrow, Hanley, Mewhinney & Strauss first reported a position in Core Laboratories in Q3 2023 and held it in 11 quarters.
Barrow, Hanley, Mewhinney & Strauss's Core Laboratories position peaked at $6.55K in Q2 2024.
186 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2026.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q2 2026, filed 12 Aug 2026.